Abstract:Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish the groundwork for their applications on a wide range of requirements. However, the application of CAR-T cell technology for solid tumors has several challenges, such as the existence of an immune-suppressing tumor microenvironment and/or inadequate tumor infiltration. Consequently, combining therapies such as CAR-T cell technology with other approaches has been proposed. The effectiveness of combining CAR-T cell with oncolytic virus therapy, with either genetically altered or naturally occurring viruses, to target tumor cells is currently under investigation, with several clinical trials being conducted. This narrative review summarizes the current advancements, opportunities, benefits, and limitations in using each therapy alone and their combination. The use of oncolytic viruses offers an opportunity to address the existing challenges of CAR-T cell therapy, which appear in the process of trying to overcome solid tumors, through the combination of their strengths. Additionally, utilizing oncolytic viruses allows researchers to modify the virus, thus enabling the targeted delivery of specific therapeutic agents within the tumor environment. This, in turn, can potentially enhance the cytotoxic effect and therapeutic potential of CAR-T cell technology on solid malignancies, with impactful results in the clinical setting.

Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option

[Progress in Clinical Studies of Chimeric Antigen Receptor Engineered T Cells for Treatment of Childhood Cancer].

CAR T-cells for pediatric solid tumors: where to go from here?

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Prospects and challenges for use of CAR T cell therapies in solid tumors

Advances of CAR-T cell immunotherapeutic targeting for malignant tumors of children

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

Oncolytic virus enhanced CAR T cell therapy in killing solid tumors

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives

Developing CAR T-Cell Therapies for Pediatric Solid Tumors

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies

CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials

From bench to bedside: the history and progress of CAR T cell therapy

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors

CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens